



Research Article

Inhibition of Inducible Nitric Oxide Synthase (iNOS) by Andrographolide and *In Vitro* Evaluation of Its Antiproliferative and Proapoptotic Effects on Cervical Cancer

Akbar Pasha,¹ Divya Vishambhar Kumbhakar ,¹ Ravinder Doneti ,¹ Kiran Kumar,² Gangappa Dharmapuri,³ Pavan Kumar Poleboyina,¹ Heena S. K.,⁴ Preethi Basavaraju,⁵ Deepthi Pasumarthi,¹ Annapurna S. D.,¹ Pavani Soujanya,⁶ I. Arnold Emeson,² Vijayalaxmi Bodiga,⁶ and Smita C. Pawar ¹

¹Department of Genetics & Biotechnology, University College of Science, Osmania University, Hyderabad, 500 007 Telangana, India

²Department of Bioinformatics, School of Biosciences & Technology, Vellore Institute of Technology, Vellore, Tamil Nadu 632014, India

³Department of Animal Biology, School of Life Sciences, University of Hyderabad, Hyderabad, 500 046 Telangana, India

⁴Department of Pathology, Osmania Medical College, Hyderabad, 500095 Telangana, India

⁵Department of Human Genetics and Molecular Biology, Bharathiar University, Coimbatore, 641046 Tamil Nadu, India

⁶Institute of Genetics and Hospital for Genetic Diseases, Osmania University, Begumpet, Hyderabad, 500007 Telangana, India

Correspondence should be addressed to Smita C. Pawar; dr.smitapawar@osmania.ac.in

Received 11 December 2020; Revised 3 February 2021; Accepted 19 February 2021; Published 16 March 2021

Academic Editor: Guodong Zhang

Copyright © 2021 Akbar Pasha et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

This work is aimed at investigating the expression levels of inducible nitric oxide synthase (iNOS) in cervical cancer and identifying a potential iNOS inhibitor. The data mining studies performed advocated iNOS to be a promising biomarker for cancer prognosis, as it is highly overexpressed in several malignant cancers. The elevated iNOS was found to be associated with poor survival and increased tumor aggressiveness in cervical cancer. Immunohistochemical and RT-PCR investigations of iNOS showed significant upregulation of endogenous iNOS expression in the cervical tumor samples, thus making iNOS a potent target for decreasing tumor inflammation and aggressiveness. Andrographolide, a plant-derived diterpenoid lactone, is widely reported to be effective against infections and inflammation, causing no adverse side effects on humans. In the current study, we investigated the effect of andrographolide on the prognostic value of iNOS expression in cervical cancer, which has not been reported previously. The binding efficacy of andrographolide was analyzed by performing molecular docking and molecular dynamic simulations. Multiple parameters were used to analyze the simulation trajectory, like root mean square deviation (RMSD), torsional degree of freedom, protein-root mean square fluctuations (P-RMSF), ligand RMSF, total number of intramolecular hydrogen bonds, secondary structure elements (SSE) of the protein, and protein complex with the time-dependent functions of MDS. Ligand-protein interactions revealed binding efficacy of andrographolide with tryptophan amino acid of iNOS protein. Cancer cell proliferation, cell migration, cell cycle analysis, and apoptosis-mediated cell death were assessed *in vitro*, post iNOS inhibition induced by andrographolide treatment (demonstrated by Western blot). **Results.** Andrographolide exhibited cytotoxicity by inhibiting the *in vitro* proliferation of cervical cancer cells and also abrogated the cancer cell migration. A significant increase in apoptosis was observed with increasing andrographolide concentration, and it also induced cell cycle arrest at G1-S phase transition. Our results substantiate that andrographolide significantly inhibits iNOS expression and exhibits antiproliferative and proapoptotic effects on cervical cancer cells.

1. Introduction

Cervical cancer (CC) ironically is still the foremost common prevalent cancer in women globally, though being the most preventable disease. The incidence of cervical cancer is on an increase, with a decrease in the age of onset [1]. Cervical cancer is most commonly caused by the infection of high-risk HPV infection (HPV16/18); the integration of the HPV genetic material into the host genome intrudes the immune response and increases the inflammation, thus promoting cancer progression [2]. The HPV infection remains inert and takes 10–20 years to develop into cancer. Persistent HPV infection alone is not sufficient to develop cervical cancer; various molecular actions and physiological factors play a vital role in the progression of the disease [3]. Smoldering inflammatory response, oxidative stress, and epigenetic changes caused by persistent HPV infection play a critical role in development of cancer [4]. The cells like macrophages, dendritic cells, and mast cells adjacent to the cancer cells create the tumor microenvironment. Inflammation is a response of the immune defense mechanism to harmful stimuli released by various infected cells; it releases cytokines, ROS, and hormones to maintain this inflammatory response. This persistent inflammation plays a significant role in carcinogenesis and contributes to cellular transformation, proliferation, invasion, and angiogenesis [5]. Inflammatory molecules involved in inflammation-mediated cervical cancer consists of reactive oxygen species (ROS), inducible nitric oxide synthase (iNOS), TNF- α , interleukin-1, IL-6, IL-8, IL-18, hypoxia-inducible factor (HIF), cyclooxygenase-2 (COX-2), matrix metalloproteinase enzyme-9 (MMP-9), and chemokines [6, 7]. Inflammation and oxidative stress are two conditions assisted by persistent HPV infection leading to carcinogenesis. Chronic inflammation impairs cell homeostasis and leads to oxidative stress thus increasing the production of reactive oxygen and nitrogen species (RONS), which in turn modulates the receptor-mediated signaling pathway, transcriptional activation for the cellular proliferation, differentiation, and death signaling as second messengers in signal transduction [8, 9]. The nitric oxide synthases are a family of isoenzymes which convert L-arginine to L-citrulline and generate NO species. Commonly, cells possess three isoforms of NOS: inducible (iNOS), endothelial (eNOS), and neural (nNOS). nNOS and eNOS are constitutively expressed in neurons and endothelial cells, respectively. Inducible NOS is expressed in macrophages, neutrophils, endothelial cells, hepatocytes, and many other cancer cell types. The NOS2 expression is triggered by cytokines and can lead to local accumulation of high concentrations of NO for extended stages [10]. The abnormal concentrations of NO implicate pathogenicity and carcinogenicity [11]. Cellular high concentration levels of NO are associated with enhanced vascular permeability facilitating tumor growth by enhanced blood flow [12]. Inducible nitric oxide synthase (iNOS/NOS2) isoform is calcium-dependent and highly expressed in many cancers. NOS2 is the only isoform to maintain the levels of NO and playing both procarcinogenic and anticarcinogenic roles in different cancers [13–15]. Various cancers known for enhanced iNOS levels are related to bacterial or viral infection like cervical, gastric, prostate, and

esophageal cancers and hepatocellular carcinoma [16–18]. iNOS expression correlates with VEGF and together is very vital for tumor growth; high levels of NO produced by the NOS2 triggers the angiogenesis process in the tumors by regulating the VEGF expression. NOS2 knockdown in SiHa and HeLa cells has shown a decrease in cell proliferation due to the decrease in the concentration of VEGF thus confirming that the NOS2 regulates the growth of cervical cancer cells in a VEGF-dependent process [14]; thus, effective inhibition of iNOS expression will thereby reduce the NO levels, triggered by inflammatory stimuli in cancer cells, and hence pronounced to be a valuable therapeutic strategy. Natural products as alternative therapeutics for treating various diseases are getting more attention in the ever-emerging medical field. Bioactive compounds from medicinal plants are known for offering relief from symptoms of various diseases. Antioxidant, anti-inflammatory, antiaging, antiatherosclerosis, and anticancerous plant-derived compounds such as polyphenols, tocopherols, ascorbic acid, carotenoids, and flavonoids with their free radical scavenging activity and physiological activities have been used extensively as therapeutics in various diseases [19–21]. Andrographolide is a bicyclic diterpenoid lactone isolated from leaves of *Andrographis paniculata*, a Chinese herbal medicine used as an anti-inflammatory drug for the treatment of bacterial infections, laryngitis, diarrhea, rheumatoid arthritis, and inflammatory diseases. Andrographolide has shown potent effect on rats suffering endotoxaemia by preventing the NO production through inhibiting iNOS [22–24]. In our current study, we establish that andrographolide exerts its anti-inflammatory effect by inhibiting the iNOS, thus reducing the NO production and curtailing the source for ROS and RNS. The aim of this study was to elucidate the interaction of andrographolide with iNOS by employing *in silico* molecular docking and molecular dynamic simulations and evaluate its inhibitory activity on the iNOS in cervical cancer HeLa cells.

2. Materials and Methods

2.1. Clinical Sample Analysis

2.1.1. Sample Collection. For the study, 40 women subjects were recruited, which included 30 cancer patients suffering from cervical lesions and 10 normal controls within a range of 30–50 yrs of age. Invasive cervical cancer patients were clinically tested for cancer diagnosis at the oncology department in MNJ Cancer Hospital, Hyderabad, India. Age-matched control subjects seeking health care with no individual history of cervical cancer were randomly procured from the department of gynecology, CC Shroff Hospital, Hyderabad, India. The study was approved by the ethical committee of MNJ Cancer Hospital, Hyderabad, India, and written consent was obtained from both the patients and control subjects involved in the study.

2.1.2. Immunohistochemical Staining (IHC). For IHC staining, paraffin-embedded specimens of both control and cervical cancer tissue were cut at a thickness of 4 mm using a microtome and eventually deparaffinized and rehydrated

followed by PBS washing. The antigen was revived in citrate buffer (0.01 M) for 15 mins. The sections of the specimen were then blocked with endogenous peroxidase for 10 mins at 37°C using H₂O₂ (3%) in methanol and further blocked with goat serum (10%, 10 mins). The sections were incubated with a primary anti-iNOS antibody (Abcam, USA) at dilution of 1:200 and kept overnight at 4°C. Post incubation, the sections were washed with PBS and were incubated with a biotin-labeled secondary antibody for 15 mins at 37°C, followed by treatment with streptavidin peroxidase reagent for 10 mins. The specimen was then subjected to 4 min incubation with 3,3'-diaminobenzidine (DAB containing 0.0018% H₂O₂ in 0.05 M Tris-HCl buffer: pH 7.6) solution, and the specimen sections were then counterstained using hematoxylin and eosin for visualization. Slides were then washed with distilled water and air-dried. The specimen slides were permanently mounted using a coverslip. IHC staining of iNOS on tissue was assessed following reported protocols [25]. The specimen sections were then observed under an inverted light microscope (Magnus INVI Olympus, Noida, India) at 4x and 10x magnification. The specimen staining was scored with intensity in the range of 0-5% taken as 0, i.e., negative; 6-25% taken as 1, i.e., weak; 26-50% taken as 2, i.e., medium; and 51-100% taken as 3, i.e., strong. The score was determined by adding the intensity of staining with its extent.

2.1.3. Quantitative RT-PCR Analysis. Total RNA was isolated from tissue samples (cervical biopsies and healthy controls) using a Qiagen RNA isolation mini kit (Qiagen, Cat No: 73404) as per the manufacturer's protocol. Gene primers and amplicon size are represented in Table 1. The quality and quantity of isolated RNA were assessed using a biospectrophotometer (Eppendorf). Total RNA (1 µg/µl) from both tumor and nontumor samples were reverse-transcribed using a PrimeScript™ 1st strand cDNA synthesis kit (Cat# 6110A), from which 1 µl of reverse-transcribed RNA was used to determine the expression of iNOS by using SYBR Green Master Mix (SYBR® Premix Ex Taq™ II Universal, Cat# RR82LR) in real-time PCR (Agilent AriaMx detection system), with a final volume of 20 µl reaction in each well. The protocol consists of 40 cycles at 95°C for 3 min (hot start), 95°C for 0.05 seconds (melting), and 52°C for 30 sec (annealing) and extension at 72°C for 20 sec. All the samples were processed in triplicates, and the beta-actin gene was used as an endogenous control for reference. The results were normalized with endogenous control. Statistical analysis for qPCR was performed using GraphPad Prism 6 (GraphPad Software Inc., San Diego, CA), and the mean ± standard deviation (SMD) of all the values was calculated by the Student *t*-test with a significant *p* value < 0.05.

2.2. In Silico Analysis

2.2.1. Data Mining of NOS2 Gene. Gene Expression Profiling Interactive Analysis (GEPIA: <http://gepia.cancer-pku.cn/>) is an interactive web application for RNA sequencing expression. We investigated the box plots of NOS2 gene expression in different cancers by comparing cancer and normal tissue from the TCGA (The Cancer Genome Atlas) datasets [26].

2.2.2. Molecular Docking Studies

(1) Ligand Structure Preparation. Molecular docking was applied to explore the mechanism of ligand binding activity and to correlate the binding score of the ligand. In our present study, we have selected natural compound andrographolide as ligand based on biological activity. The 3D structure of the phytochemical andrographolide was obtained from PubChem <https://pubchem.ncbi.nlm.nih.gov/> with ID: 5318517. Docking has been carried out by AutoDock Vina. The ligand was minimized, and the least conformation *E* = 535.66 was picked up and converted to pdbqt format.

(2) Protein Preparation for Docking. The 3D structure of the protein iNOS was downloaded from the database Protein Data Bank (PDB) (<http://www.rcsb.org/structure/4nos>) (4NOS) which is the PDB ID of the protein target. The protein pdb structure was loaded to PyRx (Vina) 0.8 and converted to macromolecules, where pdbqt format of the protein is generated that includes Kollman charges. Water was removed, and polar hydrogen was added to the protein.

(3) Molecular Dynamic Simulations. Molecular dynamic (MD) simulation was accomplished to determine the interactions between andrographolide (ligand) and nitric oxide synthase (iNOS) with PDB ID: 4NOS in an aqueous environment. Molecular dynamics is one of the most persuasive methods to study the physical nature and crucial properties of molecules such as their interaction, diffusion, and stability concerning each other. A molecular dynamic study was adopted to examine the structural dynamics and stability of the native nitric oxide iNOS (4NOS) and iNOS-andrographolide complex. By using the Glide module of the Schrodinger software, the binding affinity of iNOS-andrographolide was derived as -7.8 kcal/mol. In our present analysis, binding affinities of andrographolide and protein 4NOS were investigated by conducting static molecular docking. Molecular dynamic simulation of the andrographolide and 4NOS was performed after energy minimization of the system [27]. The OPLS force field was used for all the energy minimization and MD. Molecular dynamic trajectories were analyzed to understand the conformational changes of the native protein caused due to identified interactions between andrographolide and 4NOS. We carried out the 30 nanoseconds of molecular dynamic simulations for the protein iNOS in the native state and the iNOS complex with the ligand. Multiple parameters were used to analyze throughout the simulation trajectory, like root mean square deviation (RMSD), torsional degree of freedom, protein-root mean square fluctuations (P-RMSF), ligand RMSF, total number of intramolecular hydrogen bonds, secondary structure elements (SSE) of the protein, and protein complex with the time-dependent functions of MDS [28]. All the molecular dynamic simulations were performed with a CPU Dell Precision T5810 Intel Xeon V3 processor with 10 cores and 20 threads 240 GBs SSD 32 GBs DDR4 RAM GPU NVIDIA GeForce RTX 2060 super 8GBs DDR6 RAM 256-bit bus size.

TABLE 1: Primer sequences and amplicon sizes of iNOS and beta-actin genes used in the real-time qPCR.

Gene(s)	Forward primer	Reverse primer	Amplicon size (bp)
Beta-actin	CACCATTTGGCAATGAGCGGTTC	AGGTCTTTGCGGATGTCCACGT	135
iNOS	GCTCTACACCTCCAATGTGACC	CTGCCGAGATTTGAGCCTCATG	136

2.3. In Vitro Analysis

2.3.1. Cell Culture. Cervical carcinoma HeLa cells and normal human embryonic kidney (HEK) 293 cells were seeded and maintained in DMEM with 10% FBS and 1% penicillin-streptomycin. Both the cells were cultured in a humidified incubator with 5% CO₂ at 37°C.

2.3.2. MTT Assay for Cell Viability Assessment. Andrographolide was procured from Sigma Aldrich Lot # MKCF4812 (St. Louis, MO, U.S.A.) and was solubilized in 100 mM dimethylsulphoxide (DMSO) and further diluted with PBS. Effect of andrographolide on cell proliferation was estimated using the 3-(4,5-dimethylthiazole-2-yl)-2,5-biphenyl tetrazolium bromide (MTT) (Promega, Madison, WI, USA) assay. The HeLa and HEK cells were cultured to a density of 3×10^3 cells/well in 96-well plates and incubated at 37°C in 5% CO₂ overnight. Fresh DMEM containing an increasing concentration of andrographolide (0, 5, 10, 20, 40, and 80 μ M) was added to the wells of both HeLa and HEK cells. After 24 h incubation, 20 μ l of MTT (5 mg/ml in PBS) was added to each well and incubated for 4 h at 37°C. The plates were incubated with 100 μ l of DMSO for 30 min in a shaker incubator. The optical density was measured at 590 nm to estimate the extent of MTT reduction to formazan using a microplate reader (Bio-Rad). Three separate independent experiments were carried out, and data is represented as the mean value of triplicates. The cell viability percentage was calculated with respect to untreated cells taken as the control for each cell line. The concentration essential for 50% of growth inhibition (IC₅₀) was calculated using GraphPad Prism software.

2.3.3. Western Blotting. HeLa cells treated with andrographolide (2, 4, 8, and 10 μ M) and the untreated HeLa cells (taken as control) were grown in 6-well plates for 24 hrs, later harvested and washed with prechilled PBS. The cells were then resuspended and lysed with radioimmunoprecipitation assay (RIPA) buffer (containing phosphatase and protease inhibitor) for 60 min at 4°C. The cells were centrifuged at 12,000 rpm for 15 min at 4°C. The concentration of protein was determined using the Bradford assay. An equal quantity of 25 μ g protein lysate was loaded on SDS-PAGE and then electrotransferred onto a nitrocellulose membrane (0.2 μ M Bio-Rad cat # 1620112). The membranes were then blocked using 5% skimmed fat-free milk and incubated for 60 min. The membrane was then blotted with NOS2 (1:1000 dilution) and GAPDH (Santa Cruz Biotechnology SC-25778) followed by overnight incubation at 4°C. The membranes were washed (2 \times 15 min) with TBST (Tris-buffered saline having 0.1% Tween-20, pH 7.5) and incubated with a horseradish peroxidase-conjugated secondary antibody (Santa Cruz Biotechnology SC-2004 and SC-2005 at 1:5000 dilution)

for 1 h at room temperature and then washed with TBST multiple times. The antibody-bound protein blots were visualized by chemiluminescence (Bio-Rad ChemiDoc MP imaging™ system). The experiments were performed in three biological triplicates.

2.3.4. DAPI (4',6-Diamidino-2-phenylindole). The changes in nuclear cell morphology and chromatin structure are due to andrographolide treatment-induced apoptosis; this was analyzed using fluorescent DNA binding dye DAPI (4',6-diamidino-2-phenylindole). The HeLa cells were treated with the andrographolide doses of 5 and 10 μ M based on 50% inhibitory concentration (IC₅₀) and incubated for 24 h at 37°C with 5% CO₂. Untreated HeLa cells were the control. The cells were fixed with 3.8% paraformaldehyde and incubated with DAPI (0.5 μ g/ml in PBS) in the dark (15 min at 37°C) followed by PBS washes. The apoptotic cells with condensed and fragmented nuclei were viewed under an inverted fluorescence microscope (EVOS™ M5000, CA, USA).

2.3.5. In Vitro Scratch Wound Healing Assay. The effect of andrographolide on the migration of HeLa cells was assessed using a scratch wound healing assay. The cells were seeded on 6-well plates and incubated at 37°C, with 5% CO₂ for 24 h. The cells were grown to 90% confluence, and the monolayer of cells was scraped uniformly with a sterile p10 micropipette tip and washed with PBS to remove scraped detached cells. The cells were treated with fresh medium containing 5 and 10 μ M andrographolide and incubated at 37°C for 24 h. Cell migration into the wound of both treated and untreated HeLa cells (control) was measured at 0 h and 24 h. The photomicrographs of migrated cells in all cases were captured (at 4x magnification) using an inverted fluorescence microscope (EVOS™ M5000, CA, USA), and the scratched area was calculated with ImageJ software (version 1.50i, National Institute of Health, Bethesda, MD, USA).

2.3.6. Cell Cycle Analysis. The effect of andrographolide on the DNA of HeLa cells was analyzed using PI dye (BD Biosciences, Mountain View, CA, USA) for cell cycle analysis with BD FACSVerse™ (Becton Dickinson, USA). HeLa cells were grown to a density of 2×10^5 cells per well in a 6-well microplate, followed by treatment with 5 and 10 μ M andrographolide, for 24 h (5% CO₂, 37°C). Post incubation, the cells were collected by centrifugation and fixed with 70% chilled ethanol at -20°C then washed with PBS and resuspended in ice-cold PBS (0.5 ml). The cells were stained with PI in RNase A solution (50 μ g/ml PI and 100 μ g/ml RNase A) and incubated for 30 min at 4°C. The cell cycle analysis of both treated and untreated (control) cells was analyzed by FACSuite™ software.

2.3.7. Flow Cytometric Analysis of Apoptosis. The translocation of phosphatidylserine from the inner cell membrane to the outer cell membrane is an indicator of apoptosis [29]. Apoptosis induced by andrographolide treatment was quantitatively and qualitatively evaluated using Annexin V-FITC/propidium iodide (PI) double staining (BD Biosciences, Sparks, MD, USA). It determines and distinguishes the cells undergoing necrosis and early and late apoptosis. HeLa cells (3×10^4) were seeded in 6-well plates and treated with 5 and 10 μM of andrographolide for 24 h, and the untreated cells were taken as the control. Cells were harvested using trypsin and centrifuged (1000 g) and fixed with chilled 70% ethanol overnight at 4°C. Cell pellets were washed twice with ice-cold PBS and resuspended in 500 μl of 1x binding buffer. The cells were stained with Annexin V/FITC solution (5 μl) and PI (10 μl of 50 $\mu\text{g}/\text{ml}$) in the dark, at room temperature for 30 min followed by the addition of 400 μl binding buffer (1x), and the cells were analyzed within 60 min of staining. Cells undergoing apoptosis were monitored and measured with BD FACSVerse™ (Becton Dickinson, USA), and data was analyzed using FACSuite™ software.

2.3.8. Statistical Analysis. The data represent three independent experiments for all assessments and are represented as the mean \pm standard deviation (SD). One-way ANOVA followed by Tukey's test was used to evaluate the statistical differences, and the statistical analyses were accomplished with GraphPad Prism (version 6.01). *p* values at <0.05 were considered to be statistically significant.

3. Results

3.1. Immunoeexpression of iNOS by IHC. The expression of iNOS using a monoclonal iNOS antibody via immunohistochemistry (IHC) staining was evaluated in 5 cervical tumor tissues. Photomicrographs revealed H&E staining and immunopositivity of iNOS of cervical cancer tissue which exhibited deformed cellular morphology and irregular and deeply stained nuclei (Figure 1(b)) in contrast to normal control tissue (Figure 1(a)). IHC with iNOS antibody was observed on tissue sections of both control and cervical carcinoma epithelial cells. The iNOS was darkly stained in the cervical cancer tissue section, showing strong intensity with enhanced iNOS expression both in cytoplasm and nucleus (Figure 1(d)), and the cells show dark nuclei supporting the selective immunopositivity of iNOS, whereas the normal cervical epithelial cells were stained less (Figure 1(c)) showing weak iNOS expression.

3.2. Expression of iNOS in Cervical Tumor by RT-PCR. A real-time PCR experiment was performed to determine the expression of iNOS in cervical cancer tissue and confirmed the iNOS mRNA transcript. Our data revealed that iNOS expression was significantly upregulated and associated with cervical cancer tissue (Figure 1(e)) compared to that of control. Bar histogram clearly documented that cervical cancer patients showed a 12.21 ± 1.89 -fold increase in iNOS expression compared to control patients (Figure 1(e)).

3.3. Validation of NOS2 Gene Relative Expression. To study the relative gene expression of NOS2 gene in several cancers, the Gene Expression Profiling Interactive Analysis (GEPIA), online software based on the TCGA, and Genotype-Tissue Expression (GTEx) datasets were used. The GEPIA-provided box plot tools for differential expression analysis of NOS2 in different cancers are illustrated in Figure 2.

3.4. Docking Study. Molecular docking was applied to explore the mechanism of ligand binding activity and correlate with the ligand's binding score. The 3D structure of nitric oxide synthase protein was retrieved from the Protein Data Bank using the PDB ID: 4NOS (<https://www.rcsb.org/structure/4nos>). The docking of andrographolide and nitric oxide synthase was carried out through AutoDock Vina [30]. Inhibition constant K_i value for competitive inhibition denotes about one-half that of the IC_{50} 's numerical value; if K_i value is higher, it affects the inhibitory activity of the enzyme. Based on the docking results and considering the K_i value, we selected the second-conformer since the inhibition constant value was found to be lower compared with the first conformer (Figure 3(a)). The binding energy of the protein-ligand complex was found to be -7.8 kcal/mol with inhibition constant (K_i) of 2.17 nM. Residues such as TRP372, GLU377, and ARG199 were found to have a strong binding affinity with the ligand during the docking (Figure 3(b)). Table 2 shows the predicted binding energy values of the ligand with the target residues of iNOS (4NOS) during docking.

3.5. Molecular Dynamic Simulations

3.5.1. RMSD. The molecular dynamic (MD) simulation was carried out to understand the interactions between andrographolide (ligand) and nitric oxide synthase (iNOS) in an aqueous environment. It is one of the most persuasive methods to study molecule physical nature and crucial properties, such as interaction, diffusion, and stability. A molecular dynamics was adopted to examine the protein and iNOS-andrographolide complex's structural dynamics and stability. In our present analysis, binding affinities of andrographolide and protein 4NOS were investigated by conducting static molecular docking. The binding affinity of iNOS-andrographolide was calculated using Schrodinger's Glide module, and it was found to be -7.8 kcal/mol. Molecular dynamic simulation of the protein complex was carried out for 30 ns after energy minimization using the OPLS force field [27]. Molecular dynamic trajectories were analyzed to identify interactions between andrographolide and protein. These molecular dynamic simulations were performed by Dell Precision T5810 Intel Xeon V3 processor with ten cores and twenty threads.

RMSD analysis revealed that the native state of the protein (iNOS) has more structural deviation with maximum fluctuations of $\sim 2.4 \text{ \AA}$. In contrast, in the complex form, iNOS-andrographolide complex fluctuations were reduced to a maximum of $\sim 0.9 \text{ \AA}$ (Figure 3(c)). This reduction implies that the iNOS protein is structurally more stable upon binding to the ligand. Therefore, the ligand was found to be successfully stabilizing the iNOS (4NOS) [31].




FIGURE 1: (a, b) H&E (hematoxylin and eosin) staining of (a) control tissue and (b) cervical tumor tissues; (c, d) iNOS antibody-specific tissue staining: (c) control cervix section showing weak iNOS expression and (d) cervical carcinoma section with an elevated level of iNOS expression showing strong intensity. (e) Significantly elevated iNOS expression in cervical cancer tissue in contrast to normal control assessed by RT-PCR.

3.5.2. Torsional Degree of Freedom during MD Simulation Trajectory. Based on the contact timeline graph in Figure 4(a), interactions that occur more than 30% of the simulation time in the selected trajectory (30.12 ns) are shown where GLU377 and TRP372 residues are maintaining the contact throughout the simulation (Figures 4(a) and 4(b)) and the percentage involvement is 73% and 33%, respectively, and the same hydrogen bond interacting partners were observed in docking studies (Figure 4(c)) [32].

The ligand torsion dynamic graphs in Figure 5(a) summarize the formation of the rotational bond (RB) in the andrographolide (ligand) throughout the simulation trajectory (30.12 ns). The calculated torsional degree of freedom

illustrated rotational bonds in the andrographolide. Andrographolide molecules hold six rotational bonds amid ligand positions (I) 17 to 23, (II) 14 to 15, (III) 12 to 14, (IV) 6 to 13, (V) 20 to 24, and (VI) 5 to 25. Bonds at positions (V) and (VI) were spinning 360° during the simulation; maximum torsion angles were observed with minimal potential energy, whereas (I) spin defined ranging from -35° to -90° with torsion angle maximum with minimal potential energy was observed (Figure 5(a)). Second rotational bond (II) -85° to -140° torsion angles were found to have maximum potential energy, and the third bond (III) -30° to -85° with average potential energy maximum torsion angles was observed. Finally, the fourth rotational bond (IV) was found with




FIGURE 2: Differential expression of NOS2 gene: elevated NOS2 gene expression in different cancers. ESCA: esophageal carcinoma; CESC: cervical squamous cell carcinoma; STAD: stomach adenocarcinoma; COAD: colon adenocarcinoma; KIRC: kidney renal clear cell carcinoma; LUSC: lung squamous cell carcinoma.

minimal potential energy torsion angles. The relation between torsion potentials and the rotational bond torsion angles revealed that confirmation of the ligand is stable and helps ligand in binding to protein effectively.

3.5.3. P-RMSF. Residue contributing towards the native and complex protein structure can be assessed by the root mean square fluctuations (RMSFs) of each residue (Figure 5(b)). We inferred from the RMSF analysis that the iNOS protein in the native form has shown higher fluctuations than the iNOS-andrographolide complex with an RMSF distance of 0.45 Å for residues located between 260 and 400 residue positions (Figure 5(b)), while in the complex, the lowest peak was observed at the residue position 286. When compared with the residues, the total contacts with the ligand throughout the simulation as depicted in Figure 4(a), the corresponding residues were showing lower peaks and contributing to the stability of the protein. The overall average RMSF values of the native structure and complex were calculated as 1.165 Å and 0.96 Å, respectively (Figure 5(b)). Thus, RMSF analysis revealed that the lowest degree of flexibility was shown by the protein-ligand complex over the protein's length during the simulation (Figure 5(b)). Therefore, we concluded that these residues might play a role in directing the conformational transition. The values of RMSF of the iNOS protein and iNOS-andrographolide protein complex are illustrated in Table 3.

3.5.4. Ligand Root Mean Fluctuation (L-RMSF). The Ligand Root Mean Fluctuation (L-RMSF) of the ligand was performed on andrographolide to characterize the changes in the ligand atom's positions. The RMSF for an atom is calculated using formula:

$$\text{RMSF}_i = \sqrt{\frac{1}{T} \sum_{t=1}^T (r_i^l(t) r_i(t_{\text{ref}}))^2}. \quad (1)$$

Fluctuations of the andrographolide were broken down by atoms, corresponding to the 2D structure, and these atoms 20 (1.2 Å), 24 (1.7 Å), and 25 (1.13 Å) have demonstrated large fluctuations (Figures 6(a) and 6(b)). In contrast, the remaining atoms have minimal fluctuations well below 1 Å, indicating that the rest of the atoms were rooted inside the binding pocket. Atoms 20, 24, and 25 (Figures 6(a) and 6(b)) were solvent-exposed and could rotate easily around 6 to 13, 6 to 20, and 5 to 6, respectively. Further, we checked the drug-like properties of andrographolide, as shown in Table 4.

3.5.5. SSE Distributions by Residue Index. To understand the protein stability in the native state and complex with the ligand, we have monitored the secondary structure element (SSE). We observed that in the protein native structure, alpha helix and beta strands cover 27.02% and




FIGURE 3: (a) 3D docking image of andrographolide with iNOS (nitric oxide acid), (b) two-dimensional representation of the interaction formed by andrographolide at the catalytical active site of iNOS, and (c) RMSD of native iNOS (4NOS) and protein-ligand complex (4NOS-andrographolide).

TABLE 2: Top 5 conformers of predicted binding energy values of the protein-ligand complex during docking.

Conformers	Binding energy (kcal/mol)	Inhibition constant (Ki) (μ M)	Interacting residues
1	-8.40	697.83	ARG199, ASN370, TRP372, GLU377
2	-7.84	2.17	ARG199, TRP372, GLU377
3	-7.73	6.84	ARG199, TRP372, PRO 350, GLU377
4	-7.24	4.96	ARG199, VAL352, TRP372, GLU377
5	-6.23	26.91	ARG199, PHE369, TRP372, GLU377, TYR489

10.27%, respectively, constituted 37.3% of total residues remaining were loops, throughout the simulation (Figure 6(c)), whereas analysis revealed that the protein complex maintained about 27.06% helices and 12.77% strands constituted 40.59% of the residues leftover were

loops (Figure 6(d)). Residues present at 50, loops (L) are converted to strands (S), 240, L to S, 300 L to helices (H) and S, and 400, L to S (Figures 6(e) and 6(f)). These SSE results substantiated that the protein has attained higher stability after forming the complex.




FIGURE 4: (a) Total contacts, (b) protein-ligand H bond, and (c) MD simulation hydrogen bond percentage.

3.6. MTT Cytotoxicity Assay. The cytotoxicity and antiproliferative potentiality of different concentrations of andrographolide on HeLa and HEK cells (human embryonic kidney) were assessed using the MTT assay. The IC_{50} value after 24 h of andrographolide treatment was estimated to be $8.141 \mu\text{M}/\text{ml}$ in HeLa cells (Figure 7(a)) and was less effective against HEK cells with 50% cell death at $41.33 \mu\text{M}/\text{ml}$ (Figure 7(b)). It was observed that the IC_{50} value after 24 h in HeLa cells was 5-folds lower than that of normal cells. Andrographolide was found to be highly potent against cervical carcinoma HeLa cells in contrast to normal HEK cells and resulted in loss of cell viability in a concentration-dependent manner. Thus, andrographolide treatment was found to be cytotoxic against HeLa cells, and further, we aimed to focus further on anticancer assessment due to andrographolide.

3.7. Western Blot Analysis. Western blot analyses showed strong immunoreactivity towards antibodies of NOS2, and reduced NOS2 protein expression was observed in HeLa cells upon andrographolide treatment. We observed a dose-dependent decreased expression of NOS2 (Figures 7(c) and 7(d)), and the highest tested dose of andrographolide ($10 \mu\text{M}$) was found to be most effective against HeLa cells. Data represents the consistency of three independent experiments with GAPDH as control.

3.8. DAPI (4',6-Diamidino-2-phenylindole). Cytotoxicity-induced apoptosis due to IC_{50} dose of andrographolide treat-

ment on HeLa cells was observed using fluorescent DNA binding dye. The andrographolide-treated cervical HeLa cells showed characteristic apoptotic features containing nuclear fragmentation and irregular shape of the nucleus with intense blue fluorescence (Figures 8(b) and 8(c)). However, very less apoptotic cells having a round nucleus were observed in the case of untreated HeLa, showing faint or no blue dye validating alive cells (Figure 8(a)). The outcomes demonstrated that the andrographolide induces apoptosis in HeLa cells which corroborates with the previous reports.

3.9. In Vitro Wound Healing Scratch Assay. The wound healing scratch assay was used to determine the wound closure due to andrographolide treatment. To see the effect of andrographolide on migratory behavior of HeLa cells, the percentage of cell migration after 24 h was evaluated (Figures 8(d)–8(g)). Figure 8(d) illustrates the control with respect to all treatments. Results clearly revealed that andrographolide caused a significant inhibition of cell migration in a dose-dependent manner after 24 h treatments, with a wound area of 39.77 ± 2.54 (Figures 8(e) and 8(g)) and 17.96 ± 1.55 (Figures 8(f) and 8(g)) in 5 and $10 \mu\text{M}$, respectively, in contrast to the control, i.e., 71.59 ± 1.27 (Figure 8(d)).

3.10. Effect of Andrographolide on Cell Cycle. Inhibition of cell cycle progression with the tested doses of andrographolide was evaluated; it exhibited dose-dependent elevation in the cell population in the G1 phase which was found to be




FIGURE 5: (a) Analysis of the torsional degree of freedom during MD simulation trajectory for the rotational bonds present in the andrographolide, (b) analysis of RMS fluctuation (RMSF) trajectories generated by Schrodinger (Desmond).

TABLE 3: Values of RMSF of the protein and protein complex.

Structures	PRO350	VAL352	MET355	ASN354	PHE369	TRP372	GLU377
Protein (iNOS)	0.95	1.27	1.04	1.11	1.30	1.07	1.01
Protein complex (iNOS-andrographolide)	0.57	0.57	0.57	0.65	0.75	0.79	0.58

75.20% in 5 μ M (Figure 9(b)) and 78.40% in 10 μ M (Figure 9(c)), respectively, and in the untreated control, the cell population in the G1 phase was 59.40% (Figure 9(a)). The andrographolide treatment induced the cell cycle arrest at G1 to S transition phase (Figure 9(d)) in both the tested doses, and a notable decrease in cell population was observed in the G2/M phase in comparison to the untreated controls, and no notable changes were observed in the S phase due to induced cell cycle arrest at G1 to S transition phase (Figure 9(d)).

3.11. Andrographolide Induced Apoptosis. The effect of andrographolide on apoptosis was analyzed and evaluated

in HeLa cells after 24h treatment using Annexin V/PI dual staining. Annexin V/PI staining determined the percentage of apoptotic and nonapoptotic cells in both treated and untreated cells. A substantial increased uptake of Annexin V/PI with elevated cell count in both lower (Annexin V+/PI-) and upper right (Annexin V+/PI+) quadrants was seen in treated cells. Andrographolide treatment significantly induced early apoptosis; it was estimated to be 6.03% and 8.60% and late apoptosis as 8.74% and 12.71% in HeLa cells at 5 and 10 μ M/ml concentrations (Figures 9(f) and 9(g)). In contrast, the early and late apoptotic cell count (3.86% and 1.94%, respectively) was seen in untreated cells (Figure 9(e)). The viable




FIGURE 6: (a) 2D structure of andrographolide; (b) analysis of Ligand Root Mean Fluctuation (L-RMSF) of the andrographolide ligand. (c) SSE distributions by residue index throughout the protein structure iNOS. (d) SSE distribution by residue index of iNOS-andrographolide complex, summary of SSE composition for each trajectory frame throughout the simulation, (e) SSE composition for only protein, and (f) SSE composition for (protein complex).

TABLE 4: Drug-like properties of andrographolide.

Molecular weight (g/mol)	XLogP3	Hydrogen bond acceptor count	Hydrogen bond donor count	Index of refraction
350.4	2.2	5	3	1.568




FIGURE 7: Cell viability due to andrographolide treatment was analyzed using MTT assay on (a) HeLa cells and (b) HEK cells; (c) Western blot analysis showing decrease in NOS2 expression in HeLa cells incubated with andrographolide, and GAPDH was used as control; (d) dose-dependent reduction of iNOS was observed in response to andrographolide treatments. ns: not significant. ** and *** indicate significance at $p < 0.05$ level.

cell (Annexin V-/PI-) population percentage was found to decrease in treated cells. The results confirmed that andrographolide significantly induced apoptosis-mediated cell death in HeLa cells in a concentration- or dose-dependent manner (Figure 9(h)).

4. Discussion

Andrographolide (diterpenoid lactone compound), an active and major constituent found in leaves of *Andrographis paniculata* [33], has been reported to demonstrate biological effects such as being an anti-inflammatory [34], antiviral [35], and anticancerous [36] agent and has also been reported as an immune booster [37]. Andrographolide extracts have also been found to inhibit iNOS expression [24]; it prevents the production of reactive oxygen species [22] and is known to protect against lipid peroxidation [38]. Additionally, anti-tumor property of andrographolide has been demonstrated in several cancer cell lines, including lung [39], hepatocellular carcinoma [40], breast [41], and colon [42] cancer cells.

Andrographolide inhibits cancer cell proliferation by reducing cell viability [43] and arrests the cell cycle thereby inducing apoptosis [36, 44], and induced apoptosis could be targeted for treating cancer [45, 46]. Andrographolide exhibited anticancerous properties by inhibiting the cell proliferation, arresting cell cycle, and triggering apoptosis and cell death due to production of intracellular ROS [47, 48]. Depending on the types of cancer cells, the proapoptotic activity of andrographolide has been correlated with diverse mechanisms. Pratheeshkumar et al. [49] documented that apoptosis is induced due to andrographolide in melanoma B16F-10 cells, resulting in enhanced expression of Bax, caspase-3, and caspase-9 with downregulated Bcl-2. While in pancreatic cancer cells, apoptosis induced due to andrographolide treatment was due to STAT3 and Akt pathway activation [50]. Peng et al. [51] reported that andrographolide triggered the translocation of cytochrome c from the inner membrane of mitochondria to the cytosol leading to apoptosis. Protein binding residues of iNOS have been documented in previous literature [52, 53] and stated that the ligand




FIGURE 8: (a–c) DAPI-stained HeLa cell images of both (a) untreated control and treated andrographolide-induced apoptosis showing blue fluorescent nuclear fragmentation in HeLa cells at (b) 5 μM and (c) 10 μM , observed under an inverted fluorescence microscope (at magnification 20x). (d–g) Antimigration potency measured with andrographolide at (e) 5 μM and (f) 10 μM showing less migration than (d) control at 24 h. (g) Relative size of open scratch area (in percentage) in all the treatments and controls.

andrographolide was found to have similar interactions with the active site residues of the protein. Thus, from the docking analysis, it is suggested that the ligand could bind to the target protein more consistently for maintaining the overall stability of the complex system. The results obtained from the current study are in agreement with the earlier reports published. Via flow cytometric analysis, we have determined that andrographolide induced dose-dependent cell growth inhibition by arresting cell cycle thus activating apoptosis.

Martínez-Estrada et al. [54] reported that andrographolide promoted Snail expression (EMT transcriptional repressor) which acts as a negative regulator of claudin-1 (repressing epithelial associated proteins) indicating that it is effective against migration mediated protein in cancer cells, thus establishing its potential antimigration and anti-invasive activities. Our results reconfirm that andrographolide exposure effectively inhibited HeLa cell proliferation and migration.

NO (the iNOS product) is an endogenous short lived signaling molecule found to be involved in inflammation, tumor formation, and metastasis [55]. NO acts like free radicals and is highly reactive in biological systems, interacting with

other free radicals or molecular oxygen to produce reactive oxygen species [56]. NO is known to obstruct cell proliferation and also leads the DNA damage by deamination, strand breakage, or DNA modification [56, 57] and impedes apoptosis [58]. Kumar and Kashyap [59] reported enhanced production of NO in breast cancer due to the elevated iNOS gene, responsible for damaging cellular components including DNA and proteins. The iNOS expression is reported in prostate cancer [60, 61], colon adenocarcinoma [62, 63], breast cancer [64, 65], melanoma cancer [66, 67], esophageal carcinoma [68], cervical squamous cell carcinoma [69], stomach adenocarcinoma [70], kidney renal clear cell carcinoma [71], and lung squamous cell carcinoma [72]. Our data from the clinical samples also revealed elevated levels of iNOS as found in most of the cancers across other ethnic population worldwide. An elevated iNOS level is a potential target for treatment in advanced stages of cancer. Cervical cancer is unarguably the most treatable cancer, wherein iNOS plays a crucial role in cancer advancement and can be effectively treated with andrographolide, a plant-based natural product being used as an adjuvant therapy along with the regular drugs and treatment regime.




FIGURE 9: Flow cytometric analysis of andrographolide-treated HeLa cells showed dose-dependent (a–d) cell cycle arrest at G1/S transition phase, (e–h) Annexin V-FITC/PI-stained apoptotic cells. (a, e) Represent untreated control, (b, f) represent 5 μ M of andrographolide, and (c, g) represent 10 μ M of andrographolide. (d) Relative distribution of cell cycle percentage and (h) comparative percentage of the cell population in early and late apoptosis in control and andrographolide treatments.

Our findings *in vitro* have clearly shown that elevated iNOS expression in cervical cancer facilitates proliferation and migration and evades apoptosis. Andrographolide treatment to these cancer cells have shown to attenuate iNOS gene expression. iNOS expression is increased in cancer and stro-

mal cells and exhibited increased vascularization, indicating that iNOS promoted angiogenesis in breast carcinoma thus showing correlation of metastasis with iNOS expression [64].

Further *in vivo* studies are warranted to provide insight and better understanding to our current outcomes. Several

in vivo studies have demonstrated and confirmed the anti-inflammatory property of andrographolide, thereby depicting the significant reduction of iNOS in cancer tissues. Andrographolide administration stimulated the cytotoxicity and suppressed the tumor formation *in vivo* in oral carcinoma xenograft [73], HT-29 tumor xenografts, B16F0 melanoma [74], and colorectal carcinoma cells [75]. Zhang et al. [76] reported significant inhibition of tumor growth at both the early- and advanced-stages of insulinoma. Kumar et al. [41] reported that 20 μ M andrographolide treatment displayed significant inhibition of viability on both MDA-MB-231 and MCF-7 cells, also documenting that concentration of 50 to 100 μ M is nontoxic to normal cells. Therefore, literature authenticated that andrographolide treatment possesses the potentiality for inhibiting the tumor growth both *in vitro* and *in vivo* following different signaling pathways; thus, this study is aimed at foreseeing the effect of andrographolide on iNOS expression in cervical cancer HeLa cells, and the results are in accordance with the previous published reports.

From the results obtained, we establish the inhibitory effect of andrographolide on HeLa cells, and its property to specifically target and impede iNOS expression advocates its anticancerous property. An elevated iNOS level is an indicator of tumor aggressiveness and makes iNOS a compelling target for drug therapeutics. Andrographolide, a highly studied plant-derived natural product which is well known for its numerous beneficial properties and does not implicate any harmful side effect, can be introduced as an adjuvant drug in combination with the regular treatment regimen followed for the treatment of cervical cancer patients.

5. Conclusion

The current study has investigated the levels of iNOS in the cervical cancer patient samples, both at mRNA and protein levels. iNOS expression levels are found to be proportional to the stages of cancer and is highly elevated in the advanced stage of cancer. This formed the basis for the molecular docking, molecular dynamic, and simulation studies of iNOS protein with known ligands. Andrographolide presented encouraging unwavering results both in docking and simulation studies, hence selected for further *in vitro* analysis. Andrographolide efficiently and significantly inhibited the iNOS protein expression in a dose-dependent manner. Andrographolide also inhibited HeLa cell proliferation by arresting the cells at the G1-S phase, and further, it also induced cellular apoptosis as evinced from DAPI and Annexin V/PI staining. Our findings suggest that andrographolide exerts significant synergistic *in vitro* anticancer properties by impeding the ROS, and this paves way for their future application and use in cervical cancer treatment. The data mining has shown the significant association of the elevated levels of iNOS with an advanced stage of disease across various cancers; hence, andrographolide can also be used to treat various cancers and solid tumors. Further research is required to understand and explore the signaling mechanism being modulated by andrographolide in cervical carcinoma. Based on the current study, we strongly advocate androgra-

pholide, a plant-derived natural product as a potent inhibitor of iNOS, with its antiproliferative and proapoptotic property as an alternative promising adjuvant drug in combination with the regular treatment regimen used in cervical cancer treatment. Andrographolide could facilitate delaying the cancer progression thereby increasing the life expectancy of the patient in an advanced stage of cancer and also will contribute towards improving the quality of the life of the affected women worldwide.

Data Availability

Data supporting the productivity of this investigation are available from the corresponding author upon request.

Conflicts of Interest

The authors declare that there is no conflict of interest. No additional benefits will be received from a third party directly or indirectly by the authors.

Authors' Contributions

SCP conceptualized, designed, acquired fund, interpreted data, and edited manuscript; AP conceptualized and designed the study and conducted the study. KK and AE performed *in silico* analysis; AP, DVK, PB, PS, SDA, GD, PKP, HSK, and DP collected samples and performed the experiments on samples and *in vitro* studies. SCP, AP, DVK, RD, and KK analyzed and interpreted the data. DVK, AP, and RD drafted the manuscript. SCP and VB reviewed the manuscript. All authors have approved the manuscript in the current form.

Acknowledgments

This study was supported by grants of Dr. Smita C. Pawar received from the Science and Engineering Research Board (SERB), Govt. of India, reference Nos. SB/EMEQ-471/2014 and EEQ/2019/000569 dt 06-Jan-2020, partially funded by RUSA 2.0, and the fellowship was provided by DHR/HRD/Women Scientist/TypeV to SDA, by CSIR-UGC to AP, reference Nos. 648, and by RUSA 2.0 to DVK under CMFT, OU. The facilities were provided by DST PURSE-II.

References

- [1] Y. Liu, L. Li, Y. Li, and X. Zhao, "Research progress on tumor-associated macrophages and inflammation in cervical cancer," *BioMed Research International*, vol. 2020, Article ID 6842963, 6 pages, 2020.
- [2] A. Sreedevi, R. Javed, and A. Dinesh, "Epidemiology of cervical cancer with special focus on India," *International Journal of Women's Health*, vol. 7, pp. 405–414, 2015.
- [3] G. Pizzino, N. Irrera, M. Cucinotta et al., "Oxidative Stress: Harms and Benefits for Human Health," *Oxidative Medicine and Cellular Longevity*, vol. 2017, Article ID 8416763, 13 pages, 2017.

- [4] M. Di Domenico, G. Giovane, S. Kouidhi et al., "HPV epigenetic mechanisms related to oropharyngeal and cervix cancers," *Cancer Biology & Therapy*, vol. 19, no. 10, pp. 850–857, 2018.
- [5] S. R. Georgescu, C. I. Mitran, M. I. Mitran et al., "New insights in the pathogenesis of HPV infection and the associated carcinogenic processes: the role of chronic inflammation and oxidative stress," *Journal of Immunology Research*, vol. 2018, Article ID 5315816, 10 pages, 2018.
- [6] S. Deivendran, K. H. Marzook, and M. Radhakrishna Pillai, "The role of inflammation in cervical cancer," *Advances in Experimental Medicine and Biology*, vol. 816, pp. 377–399, 2014.
- [7] S. Ebrahimi, A. Soltani, and S. I. Hashemy, "Oxidative stress in cervical cancer pathogenesis and resistance to therapy," *Journal of Cellular Biochemistry*, vol. 120, no. 5, pp. 6868–6877, 2019.
- [8] A. Cruz-Gregorio, J. Manzo-Merino, and M. Lizano, "Cellular redox, cancer and human papillomavirus," *Virus Research*, vol. 246, pp. 35–45, 2018.
- [9] H. U. Simon, A. Haj-Yehia, and F. Levi-Schaffer, "Role of reactive oxygen species (ROS) in apoptosis induction," *Apoptosis*, vol. 5, no. 5, pp. 415–418, 2000.
- [10] H. H. W. Chen, W. C. Su, C. Y. Chou et al., "Increased expression of nitric oxide synthase and cyclooxygenase-2 is associated with poor survival in cervical cancer treated with radiotherapy," *International Journal of Radiation Oncology, Biology Physics*, vol. 63, no. 4, pp. 1093–1100, 2005.
- [11] M. Filippova, V. Filippov, V. M. Williams et al., "Cellular levels of oxidative stress affect the response of cervical cancer cells to chemotherapeutic agents," *BioMed Research International*, vol. 2014, Article ID 574659, 14 pages, 2014.
- [12] M. Smita, K. Naidu, A. N. Suryakar, S. C. Swami, R. V. Katkam, and K. M. Kumbar, "Oxidative stress and antioxidant status in cervical cancer patients," *Indian Journal of Clinical Biochemistry*, vol. 22, pp. 140–144, 2007.
- [13] F. Vanini, K. Kashfi, and N. Nath, "The dual role of iNOS in cancer," *Redox Biology*, vol. 6, pp. 334–343, 2015.
- [14] J. Dong, M. Cheng, and H. Sun, "Function of inducible nitric oxide synthase in the regulation of cervical cancer cell proliferation and the expression of vascular endothelial growth factor," *Molecular Medicine Reports*, vol. 9, no. 2, pp. 583–589, 2014.
- [15] D. D. Thomas, J. L. Heinecke, L. A. Ridnour et al., "Signaling and stress: the redox landscape in NOS2 biology," *Free Radical Biology and Medicine*, vol. 87, pp. 204–225, 2015.
- [16] M. A. Rahman, D. K. Dhar, E. Yamaguchi et al., "Coexpression of inducible nitric oxide synthase and COX-2 in hepatocellular carcinoma and surrounding liver: possible involvement of COX-2 in the angiogenesis of hepatitis C virus-positive cases," *Clinical Cancer Research*, vol. 7, no. 5, pp. 1325–1332, 2001.
- [17] A. P. Sowjanya, M. Rao, H. Vedantham et al., "Correlation of plasma nitrite/nitrate levels and inducible nitric oxide gene expression among women with cervical abnormalities and cancer," *Nitric Oxide - Biology and Chemistry*, vol. 52, pp. 21–28, 2016.
- [18] S. O. Cho, J. W. Lim, K. H. Kim, and H. Kim, "Involvement of ras and AP-1 in helicobacter pylori-induced expression of cox-2 and iNOS in gastric epithelial AGS cells," *Digestive Diseases and Sciences*, vol. 55, no. 4, pp. 988–996, 2010.
- [19] H. Anwar, G. Hussain, and I. Mustafa, "Antioxidants from natural sources," in *Antioxidants in Foods and its Applications*, InTechOpen, 2018.
- [20] S. C. Lourenço, M. Moldão-Martins, and V. D. Alves, "Antioxidants of natural plant origins: from sources to food industry applications," *Molecules*, vol. 24, no. 22, p. 4132, 2019.
- [21] D. P. Xu, Y. Li, X. Meng, T. Zhou, Y. Zhou, and J. Zheng, "Natural antioxidants in foods and medicinal plants: extraction, assessment and resources," *International Journal of Molecular Sciences*, vol. 18, no. 1, p. 96, 2017.
- [22] Y. C. Shen, C. F. Chen, and W. F. Chiou, "Andrographolide prevents oxygen radical production by human neutrophils: possible mechanism(s) involved in its anti-inflammatory effect," *British Journal of Pharmacology*, vol. 135, no. 2, pp. 399–406, 2002.
- [23] W. F. Chiou, J. J. Lin, and C. F. Chen, "Andrographolide suppresses the expression of inducible nitric oxide synthase in macrophage and restores the vasoconstriction in rat aorta treated with lipopolysaccharide," *British Journal of Pharmacology*, vol. 125, no. 2, pp. 327–334, 1998.
- [24] W. F. Chiou, C. F. Chen, and J. J. Lin, "Mechanisms of suppression of inducible nitric oxide synthase (iNOS) expression in RAW 264.7 cells by andrographolide," *British Journal of Pharmacology*, vol. 129, no. 8, pp. 1553–1560, 2000.
- [25] S.-R. Shi, C. Liu, and C. R. Taylor, "Standardization of immunohistochemistry for formalin-fixed, paraffin-embedded tissue sections based on the antigen-retrieval technique: from experiments to hypothesis," *Journal of Histochemistry and Cytochemistry*, vol. 55, pp. 105–109, 2007.
- [26] Z. Tang, C. Li, B. Kang, G. Gao, C. Li, and Z. Zhang, "GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses," *Nucleic Acids Research*, vol. 45, no. W1, pp. W98–W102, 2017.
- [27] M. Rambabu and S. Jayanthi, "Virtual screening of National Cancer Institute database for claudin-4 inhibitors: synthesis, biological evaluation, and molecular dynamics studies," *Journal of Cellular Biochemistry*, vol. 120, no. 5, pp. 8588–8600, 2019.
- [28] F. Abdul Samad, B. A. Suliman, S. H. Basha, T. Manivasagam, and M. M. Essa, "A comprehensive in silico analysis on the structural and functional impact of SNPs in the congenital heart defects associated with NKX2-5 gene - a molecular dynamic simulation approach," *PLoS One*, vol. 11, no. 5, article e0153999, 2016.
- [29] I. Vermes, C. Haanen, H. Steffens-Nakken, and C. Reutelingsperger, "A novel assay for apoptosis Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V," *Journal of Immunological Method*, vol. 184, no. 1, pp. 39–51, 1995.
- [30] H. V. Sanghani, S. H. Ganatra, and R. Pande, "Molecular - docking studies of potent anticancer agent," *Journal of Computer Science & Systems Biology*, vol. 5, pp. 12–15, 2012.
- [31] S. H. Basha, P. Bethapudi, M. Rambabu, A. Firoz, N. V. S. Viswanadha murthy M, and E. Sreenivasa reddy, "Anti-angiogenesis property by quercetin compound targeting VEGFR2 elucidated in a computational approach," *European Journal of Biotechnology and Bioscience*, vol. 2, pp. 30–46, 2014.
- [32] M. Rambabu and S. Jayanthi, "Screening approaches against claudin-4 focusing on therapeutics through molecular docking and the analysis of their relative dynamics: a theoretical approach," *Journal of Receptors and Signal Transduction*, vol. 40, no. 5, pp. 436–441, 2020.

- [33] T. Jayakumar, C.-Y. Hsieh, J.-J. Lee, and J.-R. Sheu, "Experimental and clinical pharmacology of *Andrographis paniculata* and its major bioactive phytoconstituent andrographolide," *Evidence-Based Complementary and Alternative Medicine*, vol. 2013, Article ID 846740, 16 pages, 2013.
- [34] T. Shen, W. S. Yang, Y. S. Yi et al., "AP-1/IRF-3 targeted anti-inflammatory activity of andrographolide isolated from *Andrographis paniculata*," *Evidence-based Complementary and Alternative Medicine*, vol. 2013, Article ID 210736, 16 pages, 2013.
- [35] M. M. Uttekar, T. Das, R. S. Pawar, B. Bhandari, and V. Menon, "Anti-HIV activity of semisynthetic derivatives of andrographolide and computational study of HIV-1 gp120 protein binding," *European Journal of Medicinal Chemistry*, vol. 56, pp. 368–374, 2012.
- [36] J. Li, C. Zhang, H. Jiang, and J. Cheng, "Andrographolide inhibits hypoxia-inducible factor-1 through phosphatidylinositol 3-kinase/AKT pathway and suppresses breast cancer growth," *Oncotargets and Therapy*, vol. 8, pp. 427–435, 2015.
- [37] W. Wang and J. Wang, "Immunomodulatory activity of andrographolide on macrophage activation and specific antibody response," *Acta Pharmacologica Sinica*, vol. 31, no. 2, pp. 191–201, 2010.
- [38] B. R. Choudhury and M. K. Poddar, "Andrographolide and kalmegh (*Andrographis paniculata*) extract: *in vivo* and *in vitro* effect on hepatic lipid peroxidation," *Methods and Findings in Experimental and Clinical Pharmacology*, vol. 6, no. 9, pp. 481–485, 1984.
- [39] Y. C. Lee, H. H. Lin, C. H. Hsu, C. J. Wang, T. A. Chiang, and J. H. Chen, "Inhibitory effects of andrographolide on migration and invasion in human non-small cell lung cancer A549 cells via down-regulation of PI3K/Akt signaling pathway," *European Journal of Pharmacology*, vol. 632, no. 1-3, pp. 23–32, 2010.
- [40] Y. S. Tu, D. M. Sun, J. J. Zhang et al., "Preparation and characterisation of andrographolide niosomes and its anti-hepatocellular carcinoma activity," *Journal of Microencapsulation*, vol. 31, pp. 307–316, 2013.
- [41] S. Kumar, H. S. Patil, P. Sharma et al., "Andrographolide inhibits osteopontin expression and breast tumor growth through down regulation of PI3 kinase/Akt signaling pathway," *Current Molecular Medicine*, vol. 12, no. 8, pp. 952–966, 2012.
- [42] A. Banerjee, V. Banerjee, S. Czinn, and T. Blanchard, "Increased reactive oxygen species levels cause ER stress and cytotoxicity in andrographolide treated colon cancer cells," *Oncotarget*, vol. 8, no. 16, pp. 26142–26153, 2017.
- [43] P. Pearngam, S. Kumkate, S. Okada, and T. Janvilisri, "Andrographolide inhibits cholangiocarcinoma cell migration by down-regulation of Claudin-1 via the p-38 signaling pathway," *Frontiers in Pharmacology*, vol. 10, p. 827, 2019.
- [44] T. Suriyo, N. Pholphana, N. Rangkadilok, A. Thiantanawat, P. Watcharasit, and J. Satayavivad, "*Andrographis paniculata* extracts and major constituent diterpenoids inhibit growth of intrahepatic cholangiocarcinoma cells by inducing cell cycle arrest and apoptosis," *Planta Medica*, vol. 80, no. 7, pp. 533–543, 2014.
- [45] S. Baig, I. Seevasant, J. Mohamad, A. Mukheem, H. Z. Huri, and T. Kamarul, "Potential of apoptotic pathway-targeted cancer therapeutic research: where do we stand?," *Cell Death and Disease*, vol. 7, no. 1, article e2058, 2016.
- [46] A. M. Abraha and E. B. Ketema, "Apoptotic pathways as a therapeutic target for colorectal cancer treatment," *World Journal of Gastrointestinal Oncology*, vol. 8, no. 8, pp. 583–591, 2016.
- [47] S. K. Mishra, S. Tripathi, A. Shukla, S. H. Oh, and H. M. Kim, "Andrographolide and analogues in cancer prevention," *Frontiers in Bioscience*, vol. 7, pp. 255–266, 2015.
- [48] I. Khan, F. Khan, A. Farooqui, and I. A. Ansari, "Andrographolide exhibits anticancer potential against human colon cancer cells by inducing cell cycle arrest and programmed cell death via augmentation of intracellular reactive oxygen species level," *Nutrition and Cancer*, vol. 70, no. 5, pp. 787–803, 2018.
- [49] P. Pratheeshkumar, K. Sheeja, and G. Kuttan, "Andrographolide induces apoptosis in B16F-10 melanoma cells by inhibiting NF- κ B-mediated bcl-2 activation and modulating p53-induced caspase-3 gene expression," *Immunopharmacology and Immunotoxicology*, vol. 34, pp. 143–151, 2012.
- [50] G. Q. Bao, B. Y. Shen, C. P. Pan, Y. J. Zhang, M. M. Shi, and C. H. Peng, "Andrographolide causes apoptosis via inactivation of STAT3 and Akt and potentiates antitumor activity of gemcitabine in pancreatic cancer," *Toxicology Letter*, vol. 222, no. 1, pp. 23–35, 2013.
- [51] Y. Peng, Y. Wang, N. Tang et al., "Andrographolide inhibits breast cancer through suppressing COX-2 expression and angiogenesis via inactivation of p300 signaling and VEGF pathway," *Journal of Experimental & Clinical Cancer Research*, vol. 37, no. 1, p. 248, 2018.
- [52] D. K. Ghosh and J. C. Salerno, "Nitric oxide synthases: domain structure and alignment in enzyme function and control," *Frontiers in Bioscience*, vol. 8, no. 4, pp. d193–d209, 2003.
- [53] T. O. Fischmann, A. Hruza, X. D. Niu et al., "Structural characterization of nitric oxide synthase isoforms reveals striking active-site conservation," *Nature Structural Biology*, vol. 6, no. 3, pp. 233–242, 1999.
- [54] O. M. Martínez-Estrada, A. Cullerés, F. X. Soriano et al., "The transcription factors Slug and Snail act as repressors of Claudin-1 expression in epithelial cells," *Biochemical Journal*, vol. 394, no. 2, pp. 449–457, 2006.
- [55] W. Tschugguel, C. Schneeberger, G. Unfried et al., "Expression of inducible nitric oxide synthase in human breast cancer depends on tumor grade," *Breast Cancer Research and Treatment*, vol. 56, no. 2, pp. 145–151, 1999.
- [56] S. Ambs, S. P. Hussain, and C. C. Harris, "Interactive effects of nitric oxide and the p53 tumor suppressor gene in carcinogenesis and tumor progression," *The FASEB Journal*, vol. 11, no. 6, pp. 443–448, 1997.
- [57] E. Felley-Bosco, "Role of nitric oxide in genotoxicity: implication for carcinogenesis," *Cancer and Metastasis Reviews*, vol. 17, no. 1, pp. 25–37, 1998.
- [58] S. Reveneau, L. Arnould, G. Jolimoy et al., "Nitric oxide synthase in human breast cancer is associated with tumor grade, proliferation rate, and expression of progesterone receptors," *Laboratory Investigation*, vol. 79, no. 10, pp. 1215–1225, 1999.
- [59] S. Kumar and P. Kashyap, "Antiproliferative activity and nitric oxide production of a methanolic extract of *Fraxinus micrantha* on Michigan Cancer Foundation-7 mammalian breast carcinoma cell line," *Journal of Intercultural Ethnopharmacology*, vol. 4, no. 2, pp. 109–113, 2015.
- [60] S. H. Aaltomaa, P. K. Lipponen, and V. M. Kosma, "Inducible nitric oxide synthase (iNOS) expression and its prognostic

- value in prostate cancer," *Anticancer Research*, vol. 21, pp. 3101–3106, 2001.
- [61] P. Uotila, E. Valve, P. Martikainen, M. Nevalainen, and M. Nurmi, "Increased expression of cyclooxygenase-2 and nitric oxide synthase-2 in human prostate cancer," *Urological Research*, vol. 29, no. 1, pp. 23–28, 2001.
- [62] N. Yagihashi, H. Kasajima, S. Sugai et al., "Increased in situ expression of nitric oxide synthase in human colorectal cancer," *Virchows Archiv*, vol. 436, no. 2, pp. 109–114, 2000.
- [63] F. Cianchi, C. Cortesini, O. Fantappiè et al., "Inducible nitric oxide synthase expression in human colorectal cancer: correlation with tumor angiogenesis," *The American Journal of Pathology*, vol. 162, no. 3, pp. 793–801, 2003.
- [64] M. Vakkala, K. Kahlos, E. Lakari, P. Paakko, V. Kinnula, and Y. Soini, "Inducible nitric oxide synthase expression, apoptosis, and angiogenesis in in situ and invasive breast carcinomas," *Clinical Cancer Research*, vol. 6, no. 6, pp. 2408–2416, 2000.
- [65] A. S. Bulut, E. Erden, S. D. Sak, H. Doruk, N. Kursun, and D. Dincol, "Significance of inducible nitric oxide synthase expression in benign and malignant breast epithelium: an immunohistochemical study of 151 cases," *Virchows Archiv*, vol. 447, no. 1, pp. 24–30, 2005.
- [66] O. Salvucci, M. Carsana, I. Bersani, G. Tragni, and A. Anichini, "Antiapoptotic role of endogenous nitric oxide in human melanoma cells," *Cancer Research*, vol. 61, no. 1, pp. 318–326, 2001.
- [67] D. Massi, A. Franchi, I. Sardi et al., "Inducible nitric oxide synthase expression in benign and malignant cutaneous melanocytic lesions," *The Journal of Pathology*, vol. 194, no. 2, pp. 194–200, 2001.
- [68] E. McAdam, H. N. Haboubi, G. Forrester et al., "Inducible nitric oxide synthase (iNOS) and nitric oxide (NO) are important mediators of reflux-induced cell signalling in esophageal cells," *Carcinogenesis*, vol. 33, no. 11, pp. 2035–2043, 2012.
- [69] J. Li, H. Rao, C. Jin, and J. Liu, "Involvement of the Toll-like receptor/nitric oxide signaling pathway in the pathogenesis of cervical cancer caused by high-risk human papillomavirus infection," *BioMed Research International*, vol. 2017, Article ID 7830262, 8 pages, 2017.
- [70] N. Karadayi, N. O. Kandemir, D. Yavuzer, T. Korkmaz, G. Gecmen, and F. Kokturk, "Inducible nitric oxide synthase expression in gastric adenocarcinoma: impact on lymphangiogenesis and lymphatic metastasis," *Diagnostic Pathology*, vol. 8, pp. 1–12, 2013.
- [71] L. Q. Qiu, R. Sinniah, and S. I. H. Hsu, "Coupled induction of iNOS and p53 upregulation in renal resident cells may be linked with apoptotic activity in the pathogenesis of progressive IgA nephropathy," *Journal of the American Society of Nephrology*, vol. 15, no. 8, pp. 2066–2078, 2004.
- [72] A. J. Marrogi, W. D. Travis, J. A. Welsh et al., "Nitric oxide synthase, cyclooxygenase 2, and vascular endothelial growth factor in the angiogenesis of non-small cell lung carcinoma," *Clinical Cancer Research*, vol. 6, no. 12, pp. 4739–4744, 2000.
- [73] M.-J. Hsieh, C.-W. Lin, H.-L. Chiou, S.-F. Yang, and M.-K. Chen, "Dehydroandrographolide, an iNOS inhibitor, extracted from *Andrographis paniculata* (Burm.f.) Nees, induces autophagy in human oral cancer cells," *Oncotarget*, vol. 6, no. 31, pp. 30831–30849, 2015.
- [74] J. Li, H. Y. Cheung, Z. Zhang, G. K. L. Chan, and W. F. Fong, "Andrographolide induces cell cycle arrest at G2/M phase and cell death in HepG2 cells via alteration of reactive oxygen species," *European Journal of Pharmacology*, vol. 568, no. 1–3, pp. 31–44, 2007.
- [75] Q. Lin, F. Wang, R. Yang, X. Zheng, H. Gao, and P. Zhang, "Effect of chronic restraint stress on human colorectal carcinoma growth in mice," *PLoS One*, vol. 8, no. 4, article e61435, 2013.
- [76] Q. Q. Zhang, Y. Ding, Y. Lei et al., "Andrographolide Suppress tumor growth by inhibiting TLR4/NF- κ B signaling activation in insulinoma," *International Journal of Biological Sciences*, vol. 10, no. 4, pp. 404–414, 2014.